95
Participants
Start Date
January 20, 2022
Primary Completion Date
November 30, 2028
Study Completion Date
December 31, 2028
Royal North Shore Hospital, Saint Leonards
Universitaire Ziekenhuizen Leuven, Leuven
Aarhus University Hospital, Aarhus
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan
IRCCS Ospedale San Raffaele, Milan
Physician's East Endocrinology, Greenville
Nemours Children's Clinic, Jacksonville
Endokrinologikum Gottingen, Göttingen
Ohio State University Medical Center (OSUMC), Columbus
Cincinnati Children's Hospital Medical Center, Cincinnati
Indiana University (IU) School of Medicine - University Hospital, Indianapolis
Mayo Clinic, Rochester
CHU de Lille, Lille
HCL Hopital Edouard Herriot, Lyon
HCL Hopital Femme Mere Enfant, Bron
Children's Hospital Colorado, Aurora
Departement d'Endocrinologie et Diabetes pour Enfants - AP-HP Hopital Bicetre, Le Kremlin-Bicêtre
University of California, San Francisco (UCSF) - Benioff Children's Hospital - Oakland, Oakland
Boston Children's Hospital, Boston
Bone Research and Education Centre, Oakville
Helsinki University Hospital (HUS) - The New Children's Hospital, Helsinki
Policlinico Universitario Campus Bio-Medico, Rome
Osaka University Hospital, Osaka
The University of Tokyo Hospital, Tokyo
Erasmus MC, Rotterdam
Centro Hospitalar Universitario de Lisboa Norte - Hospital de Santa Maria, Lisbon
Royal Manchester Children's Hospital, Manchester
Calcilytix Therapeutics, Inc., a BridgeBio company
INDUSTRY